Hepatitis, Opiate Dependence
Conditions
Keywords
Chronical Hepatitis C treatment, Methadone Maintenance Treatment, Pegylated Interferon and Ribavirin, 14 weeks treatment, Genotype 2 and 3
Brief summary
* To evaluate if weekly psychological follow-up make opioid dependent patients in MMT able to accomplish 14 weeks treatment with Peginterferon alfa-2a (PEG-INF) and ribavirin to the same extent than non-opioid dependents. * To determine the efficacy of this anti-HCV treatment
Detailed description
Chronic infection with the hepatitis C virus (HCV) is a health problem worldwide. In Norway, there are about 3000 patients participating in Methadone Maintenance Treatment(MMT) programs. A prevalence study at the MMT treatment unit in Kristiansand, showed that more than 90 % of 177 patients have been infected with hepatitis C. A major problem with anti-HCV treatment for this group is the lack of compliance and retention in treatment. Further, due to the high incidence of psychological disorders in opioid dependent patients, this may also complicate anti-HCV treatment. Drug addicted in MMT treatments programs may find themselves excluded from Hepatitis C treatment. Due to better treatment efficacy with the new PEG-INF's and encouraging reports from 14 weeks studies, it may be easier to motivate opioid dependents to fulfill treatment. Weekly psychological follow-up of these patients will further increase the possibility of opioid dependents in MMT to be able to complete anti-HCV treatment. The aim of this study is to focus on this patients situation, and strengthen their possibility to have a real opportunity to get treatment. We therefore wish to make a pilot study to investigate the feasibility, efficacy and psycological side-effects of the treatment.
Interventions
DRUGRibavirin
800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
DRUGPegylated Interferon
180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
Sponsors
Sorlandet Hospital HF
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Serologic evidence of hepatitis C infection, genotype 2 and 3 * Normal or elevated serum ALT activity * In MMT-programme and with at least 6 months with satisfactory drug abuse control. That means no iv injections and no or minimal use of drugs. * Male and female patients
Exclusion criteria
* Women with ongoing pregnancy or breast feeding * Untreated serious psychiatric disorders, particularly depression. * Serious drug abuse or alcohol abuse last 6 months * Intravenous drug abuse last 6 months * Hepatitis A, B or HIV infection * HCV genotype 1, 4, 5 and 6 * Leucocytes \< 3000 cells/mm3 at screening (neutrophil count \<1500 cells/mm3) * Platelet count \< 80 000 cells/mm3 at screening * Hb \<11 g/dL in women or \<12 g/dL in men at screening * Documented or presumed coronary artery disease or cerebrovascular disease * Thyroid dysfunction not adequately controlled * Epilepsy * Malignant disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Percent of patients with sustained virological response, defined as undetectable HCV RNA 24 weeks after end of treatment | 24 weeks after end of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Retention in treatment, compliance, psychological distress, measures of quality of life, perceived drug use control and urine toxicology | 2, 4, 8, 14 and 24 weeks after study start |
Countries
Norway
Outcome results
None listed